A novel microRNA signature predicts survival in stomach adenocarcinoma
Metrics: PDF 2057 views | HTML 2456 views | ?
Bowen Ding1,*, Xujie Gao1,*, Hui Li1, Liren Liu1, Xishan Hao1
1Department of Gastrointestinal Cancer Biology, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
*These authors contributed equally to this work
Liren Liu, email: [email protected]
Xishan Hao, email: [email protected]
Keywords: miRNA signature, prognostic biomarkers, overall survival, stomach adenocarcinoma
Received: November 10, 2016 Accepted: February 22, 2017 Published: March 07, 2017
Recent microRNA (miRNA) expression profiling studies suggest the clinical use of miRNAs as potential prognostic biomarkers in various malignancies. In this study, aiming to identify microRNAs with prognostic value for overall survival (OS) in stomach adenocarcinoma (STAD) patients, we analyzed the miRNA expression profiles and the associated clinical characteristics in 380 STAD samples from The Cancer Genome Atlas (TCGA) dataset. An eight-miRNA signature for predicting OS in STAD patients was identified and self-validated by survival analysis and semi-supervised principal components method. We developed a linear prognostic model composed of these miRNAs to divide patients into high- and low-risk groups according to the calculated prognostic scores. Kaplan-Meier analysis demonstrated that patients in the high-risk group had worse OS compared with patients in the low-risk group. Notably, this miRNA prognostic model showed prognostic significance to the STAD patients in early stages and the chemo-resistant patients, who would potentially benefit from additional medical interventions. Finally, this eight-miRNA signature is an independent prognostic biomarker and demonstrates a good predictive performance for 5-year survival. Thus, this signature may serve as a novel biomarker for predicting survival as well as chemotherapy response in STAD patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.